Completed Brain & Nervous System Genetics & Molecular Biology

TDP-43 Misregulation in neurodegeneration

In plain English

AI plain-English summary

A single faulty protein, TDP-43, is driving the death of nerve cells in two devastating brain diseases, and this project will uncover exactly how that happens. TDP-43 normally regulates its own production, but in people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), this self-control breaks down. The researchers have already linked specific genetic mutations and non-coding variants in patients to this breakdown. They now need to understand the molecular chain of events that turns a misregulated protein into selective brain atrophy. The team will use three approaches: mapping the protein’s interaction partners in mutant cells, screening for harmful variants in the gene’s regulatory regions using CRISPR, and tracking gene activity cell-by-cell in mouse brain tissue. Together, these experiments should reveal why certain brain regions and cell types are vulnerable while others are spared. This is fundamental science with a clear disease target. If the work succeeds, it could identify biomarkers for early diagnosis and pinpoint molecules that could be targeted by future drugs. The immediate payoff is a deeper understanding of how a single protein’s misregulation can cause such specific and devastating damage to the brain.

View original technical description
TDP-43 is a conserved RNA binding protein central to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 normally autoregulates its expression by binding to the 3’UTR of its cognate transcript. We have linked disrupted TDP-43 autoregulation to disease, showing that disease-linked TDP-43 missense mutations disturb TDP-43 autoregulation causing a gain of function, finding that ALS patients harbour non-coding variants in the 5’ and 3’UTRs of TDP-43 that could disturb TDP-43 expression and observing that TDP-43 misregulation in mice causes selective brain atrophy reminiscent of human ALS-FTD. We will follow these leads to understand the causes and consequences of TDP-43 misregulation and elucidate therapeutic targets and biomarkers for ALS-FTD. Specifically, we will dissect the TDP-43 autoregulation protein interactome in wild-type and TDP-43 missense mutant cells by performing in-cell protein-RNA interaction studies and native mass spectrometry. To determine the significance of ALS-linked UTR variants in regulating TDP-43 expression we will perform an in-vitro CRISPR/Cas9 mutagenesis screen with parallel genomic and transcriptomic sequencing. To understand how TDP-43 misregulation causes regional and cell type-specific neurodegeneration we will use in situ sequencing of mouse brain sections to obtain transcriptomic information with single cell resolution.

View the original record at the funder ↗

Researchers

Jemeen Sreedharan (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Mapping TDP-43 RNA binding partners in motor neuron differentiation and ALS pathology
Molecular mechanisms of TDP-43 mediated neurodegeneration
TDP-43: intercellular spread, cellular toxicity and protein-protein interactions in dementia
Investigating mechanisms of TDP-43 toxicity in Amyotrophic Lateral Sclerosis
Spatial Dysregulation of mRNA at the Peripheral Neuro-Glial Interface in ALS

Original classification

Senior Research Fellowship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.